$MARA DIAGONAL 260911/260925 CALL 12.0/CALL 12.5$ Rolling up by $0.5 for a potential gain in stock price. Also getting a credit of $0.29 for Rolling out.
Finally, someone spoken up about the absurdity of an orbital data centre, without tackling all the pressing issues. Naturally, it wasn't Musk, as he only speaks up when it benefits him. Musk’s Orbital Data Center Statements Below is the sequence of events where the snake oil salesman has spoken about it (In ascending date order) 31 Oct 2025 : Musk first publicly floated placing data centers in orbit in an X reply to an article discussing autonomous in-space construction. November 2025 : On “X”, Musk expanded on the concept, claiming orbital compute would become more economically viable than ground infrastructure within 3 to 5 years due to "unlimited solar power" and in-space radiative cooling. December 2025 : Following news leaks regarding a planned SpaceX listing, Musk confirmed pre-IPO d
$ULTRAGREEN AI SGD(UGS.SI)$ EPS for this share before news of US competition is approx USD 0.10. Pretty obvious that they will loss market share with Zydus and Provepharm entry but numbers will likely show only in FY2027 since Healthcare Institutions go thru vigorous process to approve procurement of new est 3 to 6 months (but I would put it as 4 months on average). Hence likely their next reporting will not be affected very much (though stock price is forward looking). Bear in mind that sales of vials is approx USD 150 per vial and it is only 1 to 2% of total FGS cost hence competitors selling at USD 75 (half price) will not change the overall healthcare cost. In fact, depending on how Ultragreen contracts with their clients, their clients may
$ULTRAGREEN AI USD(ULG.SI)$ EPS for this share before news of US competition is approx USD 0.10. Pretty obvious that they will loss market share with Zydus and Provepharm entry but numbers will likely show only in FY2027 since Healthcare Institutions go thru vigorous process to approve procurement of new est 3 to 6 months (but I would put it as 4 months on average). Hence likely their next reporting will not be affected very much (though stock price is forward looking). Bear in mind that sales of vials is approx USD 150 per vial and it is only 1 to 2% of total FGS cost hence competitors selling at USD 75 (half price) will not change the overall healthcare cost. In fact, depending on how Ultragreen contracts with their clients, their clients may